Connection
Stanley Szefler to Chemokine CCL17
This is a "connection" page, showing publications Stanley Szefler has written about Chemokine CCL17.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.239 |
|
|
|
-
Szefler S, Corren J, Silverberg JI, Okragly A, Sun Z, Natalie CR, Zitnik R, Siu K, Blauvelt A. Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II). Immunotherapy. 2024; 16(20-22):1211-1216.
Score: 0.239